Last reviewed · How we verify

NCT00376948

Phase II Trial of Novasoy®, Gemcitabine, and Erlotinib in Locally Advanced or Metastatic Pancreatic Cancer

Completed Phase 2 Results posted Last updated 25 February 2021
What this trial tests

Phase 2 trial testing genistein in Pancreatic Cancer in 20 participants. Completed in 1 March 2010.

Timeline
1 May 2005
Primary endpoint
1 March 2010
1 March 2010

Quick facts

Lead sponsorBarbara Ann Karmanos Cancer Institute
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 May 2005
Primary completion1 March 2010
Estimated completion1 March 2010
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Barbara Ann Karmanos Cancer Institute

Who can join

Adults 21 to 120, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genistein may help gemcitabine and erlotinib kill more tumor cells by making tumor cells more sensitive to the drugs. PURPOSE: This phase II trial is studying how well giving genistein together with gemcitabine and erlotinib works in treating patients with locally advanced or metastatic pancreatic cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Perspectives for cancer prevention with natural compounds.
    Amin AR, Kucuk O, Khuri FR, Shin DM. · · 2009 · cited 330× · PMID 19414669 · DOI 10.1200/jco.2008.20.6235
  2. Altered metabolism in cancer: insights into energy pathways and therapeutic targets.
    Tufail M, Jiang CH, Li N. · · 2024 · cited 265× · PMID 39294640 · DOI 10.1186/s12943-024-02119-3
  3. Drug repurposing for cancer therapy.
    Xia Y, Sun M, Huang H, Jin WL. · · 2024 · cited 229× · PMID 38637540 · DOI 10.1038/s41392-024-01808-1
  4. NF-kappaB and STAT3 signaling in glioma: targets for future therapies.
    Atkinson GP, Nozell SE, Benveniste ET. · · 2010 · cited 110× · PMID 20367209 · DOI 10.1586/ern.10.21
  5. Regulation of microRNAs by natural agents: new strategies in cancer therapies.
    Phuah NH, Nagoor NH. · · 2014 · cited 90× · PMID 25254214 · DOI 10.1155/2014/804510
  6. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics.
    Sarkar FH, Li Y. · · 2009 · cited 88× · PMID 19660870 · DOI 10.1016/j.ctrv.2009.07.001
  7. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
    Yang H, Landis-Piwowar KR, Chen D, Milacic V, et al · · 2008 · cited 70× · PMID 18537678 · DOI 10.2174/138920308784533998
  8. Clinical development of novel proteasome inhibitors for cancer treatment.
    Yang H, Zonder JA, Dou QP. · · 2009 · cited 67× · PMID 19505187 · DOI 10.1517/13543780903002074

Verify or expand the search:

Other trials of genistein

Trials testing the same drug.

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

Other Barbara Ann Karmanos Cancer Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00376948.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing